According to Benchmark, STAAR Surgical Corporation's STAA Q4 revenue was eclipsed by accelerating spending but 2011 continues to look promising.
Benchmark reported that revenue in 4Q10 expanded 8.3% to $14.4 million, which exceeded the $14.2 million consensus and Benchmark forecast. “Loss per share of $0.02 missed the $0.01 profit consensus and our $0.00 forecast. Gross margin expanded 3.1 p.p. to 64.7%, primarily due to favorably shifting product mix. Operating expense expanded
10.4% in Q4 to $10.0 million, which was $0.9 million greater than our forecast. We believe this increased investment reflects Management's preparation for FDA Toric approval in 2011. Management anticipates relatively flat 2011 operating expense growth in 2011, not withstanding our anticipation of accelerated spending upon Toric approval and launch. We reduced our 2011 EPS forecast to $0.05 from $0.07 and reduced our 2012 EPS forecast to $0.20 from $0.21. Our price target remains $10.00 based on a $6.00 core business valuation plus $4.00 for the potential upside of Toric approval.”
STAAR Surgical Corporation closed yesterday at $6.00.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in